{"filing":{"accession_number":"0001104659-26-111920","cik":"0001561921","ticker":"TELA","company_name":"TELA Bio, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-28","primary_document":"tm2626521d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926111920/tm2626521d1_8k.htm"},"events":[{"id":35732,"run_id":32931,"accession_number":"0001104659-26-111920","anchor_item_number":"1.01","event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"TELA Bio entered into a Limited Consent with its lenders on September 28, 2026, waiving the minimum Revenue covenant test for the fiscal quarters ending September 30, 2026 and December 31, 2026. This covenant waiver is a classic indicator of covenant stress—the company obtained lender consent to suspend testing of a financial covenant, signaling the company would likely fail to meet the minimum revenue requirement absent the waiver. This is a material triggering event that increases financial risk and indicates underlying operational or financial distress.","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39893,"accession_number":"0001104659-26-111920","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"TELA Bio entered into a Limited Consent with its lenders on September 28, 2026, waiving the minimum Revenue covenant test for the fiscal quarters ending September 30, 2026 and December 31, 2026. This covenant waiver is a classic indicator of covenant stress—the company obtained lender consent to suspend testing of a financial covenant, signaling the company would likely fail to meet the minimum revenue requirement absent the waiver. This is a material triggering event that increases financial risk and indicates underlying operational or financial distress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:06:50.730577+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39893,"accession_number":"0001104659-26-111920","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"TELA Bio entered into a Limited Consent with its lenders on September 28, 2026, waiving the minimum Revenue covenant test for the fiscal quarters ending September 30, 2026 and December 31, 2026. This covenant waiver is a classic indicator of covenant stress—the company obtained lender consent to suspend testing of a financial covenant, signaling the company would likely fail to meet the minimum revenue requirement absent the waiver. This is a material triggering event that increases financial risk and indicates underlying operational or financial distress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:06:50.730577+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-09-29"}]}